Venetoclax + Dexamethasone + Inotuzumab Ozogamicin
Phase 1Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
B-cell Acute Lymphoblastic Leukemia
Conditions
B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, ALL
Trial Timeline
Sep 24, 2021 → Dec 23, 2026
NCT ID
NCT05016947About Venetoclax + Dexamethasone + Inotuzumab Ozogamicin
Venetoclax + Dexamethasone + Inotuzumab Ozogamicin is a phase 1 stage product being developed by AbbVie for B-cell Acute Lymphoblastic Leukemia. The current trial status is active. This product is registered under clinical trial identifier NCT05016947. Target conditions include B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, ALL.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05016947 | Phase 1 | Active |
Competing Products
20 competing products in B-cell Acute Lymphoblastic Leukemia